E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

(2017) Nasser Hanna et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Over-expression of microRNA-940 promotes cell proliferation by targeting GSK3β and sFRP1 in human pancreatic carcinoma

(2016) Hong-wei Yang et al.   BIOMEDICINE & PHARMACOTHERAPY

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

(2016) Zhong-Yi Dong et al.   CLINICAL CANCER RESEARCH

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

(2016) Nan Zhang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer

(2016) Takehito Shukuya et al.   Journal of Thoracic Oncology

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Expression and mechanism of microRNA-181A on incidence and survival in late liver metastases of colorectal cancer

(2016) ZENGJUN LI et al.   ONCOLOGY REPORTS

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

(2015) K Abiko et al.   BRITISH JOURNAL OF CANCER

MiR-940 Inhibited Pancreatic Ductal Adenocarcinoma Growth by Targeting MyD88

(2015) Bin Song et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

(2015) K. Ota et al.   CLINICAL CANCER RESEARCH

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer

(2015) J Niu et al.   ONCOGENE

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

(2015) Shaodong Hong et al.   OncoImmunology

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

(2015) Luisa Carbognin et al.   PLoS One

MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1

(2014) Smrithi Rajendiran et al.   Molecular Cancer

Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells

(2014) Heming Li et al.   Molecular Cancer

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

(2013) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung

(2012) Jennifer M. Boland et al.   Clinical Lung Cancer

TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells

(2012) Ling Xu et al.   EUROPEAN JOURNAL OF CANCER

MicroRNA-181a – a tale of discrepancies

(2012) Aliaa M. Seoudi et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+T cells

(2011) Katarzyna Karwacz et al.   EMBO Molecular Medicine

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Ubiquitin ligase Cbl-b sensitizes leukemia and gastric cancer cells to anthracyclines by activating the mitochondrial pathway and modulating Akt and ERK survival signals

(2009) Xiujuan Qu et al.   FEBS LETTERS